AKI Risk Assessment Test System | The NephroCheck Test Global

Identify the Risk of Acute Kidney Injury—Before It’s a Problem

The NephroCheck Test was created for use alongside clinical evaluation of critically ill patients over 21. With results in just 20 minutes, the test is intended to assist the clinician in assessing the risk of moderate to severe acute kidney injury in the next 12 hours.

Identify, Stratify and Mitigate
the Risk of Acute Kidney Injury

Identify

Identify which patients may be at increased risk of developing AKI, and those who are at lower risk of developing AKI.

Stratify

Stratify patients who have a high (> 0.3) or the highest (> 2.0) risk of developing moderate to severe AKI in the next 12 hours.

Mitigate

The test results empower physicians to implement their preferred kidney-sparing strategies to potentially prevent permanent kidney damage or death.

Why is early identification of AKI important?

Dr. Peter McCullough discusses how early identification is fundamental for treating acute kidney injury. The NephroCheck Test can help inform certain adjustments to critical care management.

Click here to implement
the NephroCheck Test System.

Identifying AKI Biomarkers

The NephroCheck Test is designed to detect the presence of two key biomarkers, allowing health care professionals to assess the risk of acute kidney injury earlier and potentially mitigate severe consequences.³

Learn More About Using
the NephroCheck Test.

A Renal “Alarm System”

The NephroCheck Test produces a single numerical AKIRisk Score. Two cutoffs, selected in consultation with global experts, were judged to be clinically appropriate for the intended use.^4,5

High-Sensitivity Cutoff
(AKIRisk Score = 0.3)

A low cutoff was chosen that allows early recognition of the majority of patients who will develop AKI.*

This cutoff was selected to have high sensitivity for the primary end point and with the intent to be used in routine clinical practice to identify patients who are at high risk for AKI.
These candidates should receive kidney-sparing management strategies, such as those outlined in the KDIGO guidelines for high-risk patients.⁵

High-Specificity Cutoff
(AKIRisk Score = 2.0)

A high cutoff was also selected to allow identification of patients who will develop AKI with high specificity.

This cutoff was selected to identify the subgroup of patients who are at the highest risk of AKI.*
It can be considered for more active interventions when clinically appropriate.⁵

Learn More About Using
the NephroCheck Test.

*Moderate to severe AKI in the next 12 hours.

The NephroCheck Test AKIRisk Score Is Linked to Outcomes⁶

The NephroCheck Test AKIRisk Score is linked to outcomes.

Learn More About Using
the NephroCheck Test.

The NephroCheck Test AKIRisk Score Predicts Death or Dialysis Within Nine Months⁷

The NephroCheck Test remains a statistically significant predictor of death or dialysis after adjustment for disease severity (APACHE III) and serum creatinine.

The NephroCheck Test has been shown to be effective at predicting death and dialysis.

Learn More About Using
the NephroCheck Test.

Postoperative Biomarker-Guided Management Strategy

A recent review in Nephrology Dialysis Transplant⁸ addresses the use of the NephroCheck Test in a biomarker-guided patient management strategy based on KDIGO guidelines.

Testing for risk of acute kidney injury is a simple procedure with the NephroCheck Test

Proposed clinical application of risk assessment for patients immediately after cardiac surgery. STS, Society of Thoracic Surgery; I/O, input and output; SCr, serum creatinine; CVP, central venous pressure; NSAIDs, non-steroidal anti-inflammatory drugs; ACE, angiotensin converting enzyme inhibitor; SCVO2, central venous oxygen saturation; h/o, history of; LV Fx, left ventricular function; PA, pulmonary artery; CI, cardiac index.

Learn More About Using
the NephroCheck Test.